8-K: Cognition Therapeutics Advances Zervimesine for DLB Psychosis

Cognition Therapeutics announced plans to advance zervimesine for dementia with Lewy bodies psychosis following positive FDA feedback.

Summary

• Cognition Therapeutics, Inc. (NASDAQ: CGTX) is advancing the development of zervimesine (CT1812) for the treatment of dementia with Lewy bodies (DLB) psychosis.
• This decision follows the receipt of final minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) held on January 21, 2026.
• Management believes the best strategy is to pursue a registrational path for DLB psychosis based on the FDA's meeting minutes and strong Phase 2 SHIMMER data.
• DLB psychosis affects up to 75% of patients and currently has no approved medications, with traditional antipsychotics often contraindicated.
• The Phase 2 SHIMMER study showed zervimesine had a robust impact on neuropsychiatric symptoms, resulting in an 86% slowing of decline on the 12-item neuropsychiatric inventory (NPI-12) versus placebo.
• Zervimesine did not impair participants' motor skills and showed a directionally favorable impact on cognitive fluctuations, memory, movement, and activities of daily living.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a highly positive development, given the clear regulatory path forward for a drug addressing a significant unmet medical need with promising Phase 2 data and a favorable safety profile.

Positives

• FDA meeting minutes support a registrational path for zervimesine in DLB psychosis, expediting its potential route to market.
• Phase 2 SHIMMER data demonstrated an 86% slowing of decline in neuropsychiatric symptoms (NPI-12) compared to placebo.
• Zervimesine did not impair motor skills in DLB patients, a significant advantage over traditional antipsychotics which can worsen motor function.
• The drug showed directionally favorable impacts on cognitive fluctuations, memory, movement, and activities of daily living.
• Addresses a significant unmet medical need, as there are no approved medications for DLB psychosis and current treatments are often contraindicated.
• The SHIMMER study was supported by a $30 million grant from the National Institute on Aging (NIH), and the ongoing START study has $81 million in grant support.

Risks

• The FDA may disagree with the planned clinical study design for DLB and determine it is not registrational, potentially requiring additional studies.
• Competition from other pharmaceutical companies developing treatments for neurodegenerative disorders.
• Ability to secure new and retain existing grant funding is crucial for ongoing research and development.
• Challenges in growing and managing growth, maintaining relationships with suppliers, and retaining key management and employees.
• Uncertainties inherent in preliminary data, pre-clinical studies, and earlier-stage clinical trials being predictive of later-stage trial results.
• The timing, scope, and likelihood of regulatory filings and approvals for product candidates are uncertain.
• Changes in applicable laws or regulations could impact development and approval processes.
• Adverse effects from broader economic, business, or competitive factors, including ongoing economic uncertainty.
• Estimates of expenses and profitability may not be accurate.
• The evolution of the markets in which the company competes could present challenges.
• Ability to implement strategic initiatives and continue to innovate existing products.
• Ability to defend intellectual property rights.
• Impacts of ongoing global and regional conflicts on business, supply chain, and labor force.
• Ability to maintain the listing of common stock on the Nasdaq Capital Market.

Future Outlook

Cognition Therapeutics expects to meet with the FDA Division of Psychiatry by midyear 2026 to discuss the DLB psychosis program. The next study for DLB will focus on measuring neuropsychiatric symptoms (hallucinations, delusions) and behavioral symptoms (anxiety, aggression, agitation) using established validated endpoints. Participants will be randomized to either 100mg of oral zervimesine or placebo daily, with eligibility for an open-label extension study afterward.

Management Comments

• Anthony O. Caggiano, MD, PhD, Cognition's CMO: "Based on the Agencys meeting minutes and the strength of our Phase 2 SHIMMER data in the psychiatric and behavioral domain, we believe the best strategy is to pursue a registrational path for the treatment of DLB psychosis."
• Lisa Ricciardi, Cognition's president and CEO: "There are no approved medications for DLB psychosis, which effects a majority of patients with the disease... We showed in Phase 2 that zervimesines impact on neuropsychiatric symptoms did not impair participants motor skills... Subject to alignment with the FDA, we believe this regulatory program will allow us to expedite zervimesines path to market, where it can meet a critical need for DLB patients."

Industry Context

StockSavvy.ai notes the significant unmet medical need in dementia with Lewy bodies (DLB) psychosis, where current antipsychotics are often contraindicated or poorly tolerated due to severe side effects like parkinsonism. Zervimesine's potential to address these debilitating symptoms without worsening motor function positions it favorably in a market lacking approved, safe, and effective treatments. This development could establish a new standard of care if successful.

Comparison to Industry Standards

• Traditional antipsychotics, such as haloperidol, are contraindicated in patients with DLB due to the risk of severe parkinsonism, sedation, and immobility.
• Benzodiazepines can also worsen motor function in DLB patients.
• Zervimesine's Phase 2 results showed no impairment of participants' motor skills and even a directionally favorable impact on cognitive fluctuations, memory, movement, and activities of daily living, differentiating it significantly from existing, unsuitable treatment options.

Stakeholder Impact

• Shareholders: Potential for increased company valuation due to positive regulatory progress and addressing a significant market need.
• Patients with DLB Psychosis: Potential access to a much-needed, safer, and effective treatment option where none currently exist.
• Caregivers: Reduced burden due to potential improvement in patient symptoms and quality of life.
• Employees: Continued and potentially expanded development work, contributing to job security and growth opportunities.

Next Steps

• Meet with the FDA Division of Psychiatry by midyear 2026 to discuss the DLB psychosis program.
• Initiate the next study for DLB, focusing on the measurement of neuropsychiatric symptoms (hallucinations, delusions) and behavioral symptoms (anxiety, aggression, agitation) using established validated endpoints.
• Participants in the next study will be randomized to either 100mg of oral zervimesine or placebo daily for the study period.
• Participants will be eligible to enroll in an open-label extension study after completing the main study period.

Key Dates

Recommendation

The FDA's support for a registrational path for zervimesine in DLB psychosis, combined with compelling Phase 2 data showing significant slowing of decline in neuropsychiatric symptoms without motor impairment, addresses a critical unmet medical need where current treatments are contraindicated. This significantly de-risks the development pathway and enhances the drug's market potential, making it a strong investment opportunity.

Keywords

Dementia with Lewy Bodies, DLB Psychosis, Zervimesine, CT1812, Neurodegenerative Disorders, Clinical-Stage Biopharmaceutical, FDA, Phase 2 SHIMMER Study, Neuropsychiatric Symptoms, Alzheimer's Disease, Sigma-2 Receptor